Duration of mucositis and dysphagia following radiotherapy (+cetuximab) for locoregionally advanced head and neck cancer

被引：0
|
作者：
Bonner, J. A.
Harari, P. M.
Giralt, J.
Raben, D.
Jassem, J.
Azarnia, N.
Spencer, S. A.
Rowinsky, E. K.
Amellal, N.
Baselga, J. L.
Ang, K.
机构：
[1] Univ Alabama, Birmingham, AL USA
[2] Univ Wisconsin, Madison, WI USA
[3] Hosp Gen Valle Hebron, Barcelona, Spain
[4] Univ Colorado, Aurora, CO USA
[5] Med Univ Gdansk, Gdansk, Poland
[6] ImClone Syst, Branchburg, NJ USA
[7] Merck Lipha Sante France, Paris, France
[8] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2007.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：S137 / S137
页数：1
相关论文
共 50 条
  • [1] Cetuximab or cisplatin as a radiosensitizer in locoregionally advanced head and neck cancer: recent results
    Bonner, James A.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 (03) : 234 - 237
  • [2] Concurrent Cetuximab and Radiation Therapy in Patients with Locoregionally Advanced Head and Neck Cancer
    Cheng, H. C.
    Ngan, R. K. C.
    Au, K. H.
    [J]. HONG KONG JOURNAL OF RADIOLOGY, 2012, 15 (01): : 29 - 35
  • [3] Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?
    Bourhis, Jean
    Lefebvre, Jean-Louis
    Vermorken, Jan B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 1979 - 1989
  • [4] The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer
    Vokes, EE
    Haraf, DJ
    Kies, MS
    [J]. SEMINARS IN ONCOLOGY, 2000, 27 (04) : 34 - 38
  • [5] Radiotherapy combined with Cetuximab for locally advanced head and neck cancer
    Acevedo-Henao, C-M
    Valette, G.
    Marianowski, R.
    Pradier, O.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 96 - 96
  • [6] Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer
    Saraswathula, Anirudh
    Chen, Michelle M.
    Colevas, A. Dimitrios
    Divi, Vasu
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2019, 145 (12) : 1160 - 1167
  • [7] Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment
    Caudell, Jimmy J.
    Sawrie, Stephen M.
    Spencer, Sharon A.
    Desmond, Renee A.
    Carroll, William R.
    Peters, Glenn E.
    Nabell, Lisle M.
    Meredith, Ruby F.
    Bonner, James A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03): : 676 - 681
  • [8] Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer
    Bonner, JA
    Giralt, J
    Harari, PM
    Jones, C
    Cohen, R
    Sur, RK
    Raben, D
    Kies, MS
    Azarnia, N
    Molloy, PT
    Ang, KK
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S147 - S148
  • [9] Predictors of severe dysphagia following radiotherapy for head and neck cancer
    Petersson, Kerstin
    Finizia, Caterina
    Tuomi, Lisa
    [J]. LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2021, 6 (06): : 1395 - 1405
  • [10] Cetuximab and radiotherapy for head and neck cancer
    Posner, MR
    Wirth, LJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06): : 634 - 636
12345